Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief
SEATTLE, Aug. 13, 2013
SEATTLE, Aug. 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a
clinical-stage biopharmaceutical company committed to discovering, developing
and commercializing products targeting inflammation, coagulopathies and
disorders of the central nervous system, has announced that Michael A.
Jacobsen is joining the company as vice president, finance and chief
"Mike's experience leading finance teams responsible for the commercial launch
of biopharmaceutical products including Cialis^®, one of the most successful
drugs on the market, will be instrumental as we anticipate marketing approval
for OMS302 next year," stated Gregory A. Demopulos, M.D., Omeros' chairman and
chief executive officer. "With his deep background in accounting, business
management and finance, I expect that Mike will begin contributing immediately
to Omeros' planned transition to a commercial company."
"I am impressed by what the Omeros team has accomplished and by the tremendous
potential of Omeros' development programs," said Mr. Jacobsen. "These are
exciting times for Omeros, and I look forward to helping the company achieve
commercial success for a long line of products, starting with OMS302."
Mr. Jacobsen brings over 30 years of senior business management and accounting
experience to Omeros and led the finance teams responsible for the commercial
launch of Cialis® and Recothrom^®. His experience includes more than a decade
of service as a senior finance and accounting officer with publicly traded
medical research, drug development and biotechnology companies. Omeros' board
of directors will appoint Mr. Jacobsen to his position of vice president,
finance and chief accounting officer.
Most recently, Mr. Jacobsen was vice president of finance and chief accounting
officer of Sarepta Therapeutics, Inc. (formerly AVI BioPharma, Inc.). From
2007 to 2011, he was vice president and chief accounting officer at
ZymoGenetics, Inc., a publicly traded biotechnology company acquired by
Bristol-Myers Squibb (BMS) in October 2010, where his responsibilities
included managing all aspects of accounting and financial information, tax
planning and compliance, SEC reporting, annual audit and quarterly reviews,
and purchasing. Subsequent to the merger, Mr. Jacobsen was responsible for
migrating the ZymoGenetics financial operations and systems to BMS. Prior to
ZymoGenetics, Mr. Jacobsen held various roles from 2001 to 2007 at ICOS
Corporation, a publicly traded biotechnology company acquired by Eli Lilly in
January 2007, including senior director of finance and corporate controller.
Before joining ICOS, Mr. Jacobsen held the position of vice president of
finance/chief financial officer at two publicly traded e-commerce and software
companies. Mr. Jacobsen is a certified public accountant and received his
bachelor's degree in accounting from Idaho State University.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has six clinical development programs.
Omeros may also have the near-term capability, through its GPCR program, to
add a large number of new drug targets and their corresponding compounds to
the market. Behind its clinical candidates and GPCR platform, Omeros is
building a diverse pipeline of protein and small-molecule preclinical programs
targeting inflammation, coagulopathies and central nervous system disorders.
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, which are subject to the "safe harbor" created by those
sections for such statements. These statements include, but are not limited
to, the potential commercial launch timeline for OMS302; the potential
benefits of Omeros' product candidates; and its capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management only as of
the date of this press release. Omeros' actual results could differ materially
from those anticipated in these forward-looking statements for many reasons,
including, without limitation, the risks, uncertainties and other factors
described under the heading "Risk Factors" in the Company's Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission on August 9,
2013. Given these risks, uncertainties and other factors, you should not place
undue reliance on these forward-looking statements, and the Company assumes no
obligation to update these forward-looking statements publicly, even if new
information becomes available in the future.
SOURCE Omeros Corporation
Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, 360.668.3701, email@example.com
Press spacebar to pause and continue. Press esc to stop.